Charles C. Wykoff, MD, PhD

Associate Professor of Clinical Ophthalmology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Diabetic retinopathy Macular degeneration Vitreoretinal surgery
Education & Training

Internship, Harvard University
MD, Harvard University
Clinical Fellowship, Bascom Palmer Eye Inst & Hosp
Residency, Bascom Palmer Eye Inst & Hosp

Suprachoroidal space alterations following delivery of triamcinolone acetonide: Post-hoc analysis of the phase 1/2 HULK study of patients with diabetic macular edema
Lampen, SIR, Khurana, RN, Noronha, G, Brown, DM & Wykoff, CC 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 9, pp. 692-697. DOI: 10.3928/23258160-20180831-07

Predictors of visual acuity outcomes following vitrectomy for idiopathic macular hole
Amram, AL, Mandviwala, MM, Ou, WC, Wykoff, CC & Shah, AR 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 8, pp. 566-570. DOI: 10.3928/23258160-20180803-03

Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial
TREX-AMD Study Group 2018, American Journal of Ophthalmology, vol. 192, pp. 84-90. DOI: 10.1016/j.ajo.2018.05.008

Ultra-wide-field fluorescein angiography–guided normalization of ischemic index calculation in eyes with retinal vein occlusion
Wang, K, Falavarjani, KG, Nittala, MG, Sagong, M, Wykoff, CC, van Hemert, J, Ip, M & Sadda, SR 2018, Investigative Ophthalmology and Visual Science, vol. 59, no. 8, pp. 3278-3285. DOI: 10.1167/iovs.18-23796

When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies
Eichenbaum, DA, Buznego, C, Weng, CY, Dhoot, DS, Wykoff, CC & Sheth, VS 2018, Ophthalmic surgery, lasers & imaging retina, vol. 49, no. 7, pp. S5-S15. DOI: 10.3928/23258160-20180621-01

Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema
Payne, JF, Clark, WL, Bruce, BB, Wykoff, CC, Brown, DM, Menke, BM, Iverson, SM, Allen, KF, Boyer, DS & Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group 2018, Ophthalmology. DOI: 10.1016/j.ophtha.2018.03.046

Five-year outcomes of surgically treated symptomatic epiretinal membranes with and without internal limiting membrane peeling
Sultan, H, Wykoff, CC & Shah, AR 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 5, pp. 296-302. DOI: 10.3928/23258160-20180501-02

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study
Wykoff, CC, Ou, WC, Khurana, RN, Brown, DM, Lloyd Clark, W & Boyer, DS 2018, British Journal of Ophthalmology, vol. 102, no. 5, pp. 631-636. DOI: 10.1136/bjophthalmol-2017-310941

Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study
Kwon, S, Wykoff, CC, Brown, DM, van Hemert, J, Fan, W & Sadda, SR 2018, British Journal of Ophthalmology, vol. 102, no. 8, pp. 1066-1071. DOI: 10.1136/bjophthalmol-2017-311475

Identification of factors to increase efficacy of telemedicine screening for diabetic retinopathy in endocrinology practices using the Intelligent Retinal Imaging System (IRIS) platform
Naik, S, Wykoff, CC, Ou, WC, Stevenson, J, Gupta, S & Shah, AR 2018, Diabetes research and clinical practice, vol. 140, pp. 265-270. DOI: 10.1016/j.diabres.2018.04.011

Neovascular age-related macular degeneration management in the third year: Final results from the TREX-AMD randomised trial
Wykoff, CC, Ou, WC, Croft, DE, Payne, JF, Brown, DM, Clark, WL, Abdelfattah, NS & Sadda, SVR 2018, British Journal of Ophthalmology, vol. 102, no. 4, pp. 460-464. DOI: 10.1136/bjophthalmol-2017-310822

Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial
Ou, WC, Lampen, SIR & Wykoff, CC 2018, Ophthalmic surgery, lasers & imaging retina, vol. 49, no. 4, pp. 258-264. DOI: 10.3928/23258160-20180329-08

Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial
SCORE2 Investigator Group 2018, JAMA Ophthalmology, vol. 136, no. 4, pp. 337-345. DOI: 10.1001/jamaophthalmol.2017.6843

When your diabetic patient requires anterior segment attention: How to successfully manage patients with diabetes during cataract surgery
Steinle, NC & Wykoff, CC 2018, Retina Today, vol. 2018, no. March, pp. 50-52.

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
Wykoff, CC, Clark, WL, Nielsen, JS, Brill, JV, Greene, LS & Heggen, CL 2018, Journal of managed care & specialty pharmacy, vol. 24, no. 2-a Suppl, pp. S3-S15. DOI: 10.18553/jmcp.2018.24.2-a.s3

Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial
on behalf of the TREX-AMD Study Group 2018, Graefes Archive for Clinical and Experimental Ophthalmology, pp. 1-8. DOI: 10.1007/s00417-017-3888-2

Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion. Three-Year Randomized DAVE Trial
Brown, DM, Ou, WC, Wong, TP, Kim, RY, Croft, DE & Wykoff, CC 2018, Ophthalmology. DOI: 10.1016/j.ophtha.2017.11.026

Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial
Diabetic Retinopathy Clinical Research Network 2018, JAMA Ophthalmology, vol. 136, no. 1, pp. 29-38. DOI: 10.1001/jamaophthalmol.2017.4914

Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging with Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy
Aiello, LP, Odia, I, Glassman, AR, Melia, M, Jampol, LM, Bressler, NM, Kiss, S, Silva, PS, Wykoff, CC & Sun, JK 2018, JAMA ophthalmology. DOI: 10.1001/jamaophthalmol.2018.4982

Positive visual phenomena following implantation of the argus II retinal prosthesis
Sadaka, A, Iqbal, C, Nazari, H, Berry, S, Wykoff, CC, Humayun, MS & Lee, AG 2017, Ophthalmic Surgery Lasers and Imaging Retina, vol. 48, no. 12, pp. 1022-1025. DOI: 10.3928/23258160-20171130-11